Johnson & Johnson (NYSE:JNJ) has discontinued a combination therapy involving its experimental antibody therapy, nipocalimab, for rheumatoid arthritis after a failure in a mid-stage trial, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results